Serum cortistatin levels in patients with ocular active and ocular inactive Behcet Disease
dc.authorid | 0000-0003-4468-3985 | en_US |
dc.contributor.author | Balbaba, Mehmet | |
dc.contributor.author | Ulaş, Fatih | |
dc.contributor.author | Postacı, Sevinç Arzu | |
dc.contributor.author | Öz, Burak | |
dc.contributor.author | Aydın, Süleyman | |
dc.date.accessioned | 2021-06-23T19:55:02Z | |
dc.date.available | 2021-06-23T19:55:02Z | |
dc.date.issued | 2020 | |
dc.department | BAİBÜ, Tıp Fakültesi, Cerrahi Tıp Bilimleri Bölümü | en_US |
dc.description.abstract | Purpose: To evaluate serum cortistatin (CST) levels in patients with ocular active and ocular inactive Behcet disease (BD) and its relationship with disease activity. Methods: 24 BD patients with ocular active, 24 BD patients with ocular inactive patients and 24 healthy control subjects were included in the study. Results: In ocular active and ocular inactive BD patients and healthy control subjects, the mean serum CST levels were 4.38 +/- 1.63ng/ml, 5.46 +/- 1.81ng/ml and 7.56 +/- 1.73ng/ml, respectively. ESR, serum CRP, CST levels and NLR were significantly different between the groups (p < 0.001 for all). The CST levels were similar between ocular active and inactive BD patient groups (p = 0.197). ESR, CRP and NLR were significantly higher in ocular active BD patients compared to ocular inactive BD patients and healthy control subjects (p < 0.05 for all). Conclusion: Serum CST level was significantly lower in BD patients. CST may be a neuropeptide that plays a role in the pathogenesis of BD. | en_US |
dc.identifier.doi | 10.1080/09273948.2019.1610461 | |
dc.identifier.endpage | 605 | en_US |
dc.identifier.issn | 0927-3948 | |
dc.identifier.issn | 1744-5078 | |
dc.identifier.issue | 4 | en_US |
dc.identifier.pmid | 31314641 | en_US |
dc.identifier.scopus | 2-s2.0-85070287873 | en_US |
dc.identifier.scopusquality | Q1 | en_US |
dc.identifier.startpage | 601 | en_US |
dc.identifier.uri | https://doi.org/10.1080/09273948.2019.1610461 | |
dc.identifier.uri | https://hdl.handle.net/20.500.12491/10711 | |
dc.identifier.volume | 28 | en_US |
dc.identifier.wos | WOS:000476125200001 | en_US |
dc.identifier.wosquality | Q2 | en_US |
dc.indekslendigikaynak | Web of Science | en_US |
dc.indekslendigikaynak | Scopus | en_US |
dc.indekslendigikaynak | PubMed | en_US |
dc.institutionauthor | Ulaş, Fatih | |
dc.language.iso | en | en_US |
dc.publisher | Taylor & Francis Inc | en_US |
dc.relation.ispartof | Ocular Immunology And Inflammation | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | Behcet Disease | en_US |
dc.subject | Behcet Disease Ocular Attack Score 24 | en_US |
dc.subject | Cortistatin | en_US |
dc.subject | C-reactive Protein | en_US |
dc.subject | Erythrocyte Sedimentation Rate | en_US |
dc.subject | Neutrophil-lymphocyte Ratio | en_US |
dc.title | Serum cortistatin levels in patients with ocular active and ocular inactive Behcet Disease | en_US |
dc.type | Article | en_US |
Dosyalar
Orijinal paket
1 - 1 / 1
Küçük Resim Yok
- İsim:
- mehmet-balbaba.pdf
- Boyut:
- 598.98 KB
- Biçim:
- Adobe Portable Document Format
- Açıklama:
- Tam Metin/Full Text